Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.
Abstract
Summary— In a controlled trial the effects of the osteoclast inhibitor disodium pamidronate were studied over a 6‐month period in men with metastatic bone disease from prostate cancer. Using serial biochemical measurement of metabolic bone activity, and complementary subjective and quantitative bone histology, the effects of pamidronate were evaluated in tumour‐free and metastatic regions of the skeleton, enabling analysis of the differential mechanisms of bone destruction in this disease. Following treatment, abnormally high markers of bone breakdown fell significantly (fasting urine hydroxyproline/creatinine (OHP): P < 0.05; fasting urine calcium excretion (Ca E ): P <0.0001), confirming that activated osteoclasts play an integral role in the osteolytic process. Serial histomorphometry of bone from tumour‐free areas showed that pamidronate restored abnormal levels of bone erosion to normal in 93% of cases. Suppression of bone destruction was also evident within metastases, although this was incomplete. The results confirm that osteoclast overactivity is responsible for a significant proportion of the accelerated osteolysis seen in both tumour‐free and infiltrated bone in patients with prostate cancer. The differential effects in tumour‐free and infiltrated bone suggest that the mechanisms of osteoclast activation may differ in metastatic and non‐metastatic regions of the skeleton.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prostate cancer bone metastases usually look osteoblastic, yet bone resorption is often raised in these lesions.
“While bone metastasis lesions in prostate cancer patients typically have an osteoblastic (osteosclerotic) appearance, there is evidence that bone resorption is also frequently increased in these lesions (346,347).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [346]
Cites
(1990) · Elsevier eBooks · doi:10.1016/c2009-0-34738-8 · Cited by 1,073 · see citing works
Quantitative structural analysis of human cancellous bone
Merz, W. A., & Schenk, R. (2008) · Acta Anatomica · doi:10.1159/000143440 · Cited by 299 · see citing works
Mechanisms of bone destruction in the development of skeletal metastases
Galasko, C. S. B. (1976) · Nature · doi:10.1038/263507a0 · Cited by 272 · see citing works
Anderson, C. (1994) · Bone and Mineral · doi:10.1016/s0169-6009(08)80063-3 · Cited by 258 · see citing works
Direct resorption of bone by human breast cancer cells in vitro
Eilon, G., & Mundy, G. R. (1978) · Nature · doi:10.1038/276726a0 · Cited by 237 · see citing works
Calcium, Phosphate, and Magnesium Metabolism
Wilson, F. E. (1977) · Military Medicine · doi:10.1093/milmed/142.11.906c · Cited by 236 · see citing works
Hypercalcemia of malignancy revisited.
Mundy, G. R. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113555 · Cited by 190 · see citing works
Generalised Increase in Bone Resorption in Carcinoma of the Prostate
Urwin, G. H., PERCIVAL, R. C., HARRIS, S., et al. (1985) · British Journal of Urology · doi:10.1111/j.1464-410x.1985.tb07040.x · Cited by 144 · see citing works
Percival, R. C., Urwin, G. H., Harris, S., et al. (1987) · PubMed · Cited by 124 · see citing works
Response of bone to tumor invasion
Milch, R. A., & Changus, G. W. (1956) · Cancer · doi:10.1002/1097-0142(195603/04)9:2 · Cited by 121 · see citing works
Connolly, J. M., & Rose, D. P. (1990) · The Prostate · doi:10.1002/pros.2990160304 · Cited by 120 · see citing works
Carcinoids: The association of histologic growth pattern and survival
Johnson, L. A., Lavin, P. T., Moertel, C. G., Weiland, L. H., Dayal, Y., Doos, W. G., Geller, S. A., Cooper, H. S., Nime, F. A., Massé, S., et al. (1983) · Cancer · doi:10.1002/1097-0142(19830301)51:5 · Cited by 118 · see citing works
Sitaras, N. M., Sariban, E., Bravo, M., Pantazis, P., & Antoniades, H. N. (1988) · PubMed · Cited by 93 · see citing works
Epidermal Growth Factor Receptor mRNA Levels in Human Prostatic Tumors and Cell Lines
Morris, G. L., & Dodd, J. G. (1990) · The Journal of Urology · doi:10.1016/s0022-5347(17)40253-9 · Cited by 93 · see citing works
Influence of a diphosphonate on the cellular aspect of young bone tissue
Plasmans, C. M. T., Jap, P. H. K., Kuijpers, W., Slooff, T. J. J. H., & Wijers, M. (1980) · Calcified Tissue International · doi:10.1007/bf02408548 · Cited by 72 · see citing works
Pollard, M., & Luckert, P. H. (1985) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/75.5.949 · Cited by 52 · see citing works
Osteomalacia and carcinoma of prostate with major redistribution of skeletal calcium
Hosking, D. J., Chamberlain, M. J., & Shortland-Webb, W. R. (1975) · British Journal of Radiology · doi:10.1259/0007-1285-48-570-451 · Cited by 41 · see citing works
Stronski, S. A., Bettschen-Camin, L., Wetterwald, A., et al. (1988) · Calcified Tissue International · doi:10.1007/bf02553751 · Cited by 31 · see citing works
Nemoto, R., Kanoh, S., Koiso, K., et al. (1988) · The Journal of Urology · doi:10.1016/s0022-5347(17)41848-9 · Cited by 21 · see citing works
Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin.
CHARHON, S. A., Chapuy, M. C., Delvin, E. E., et al. (1985) · PubMed · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works
Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452 · see citing works
- Authors
- CLARKE, N. W., McCLURE, J., & GEORGE, N. J. R.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- CLARKE, N. W.
- Venue
- British Journal of Urology
- Publisher
- Wiley
- Published
- 1992-01
- Volume
- 69
- Issue
- 1
- Pages
- 64-70
- ISSN
- 0007-1331 (ISSN-L)
- OpenAlex
- W1967168865
- Cited by
- 78
- References
- 20
- Citations by year
- 2025: 1 · 2017: 1 · 2014: 2
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Keywords
- osteoclast inhibitors, metastatic prostate cancer, bone metastasis, osteolytic bone destruction, osteoclast activation, bone resorption, urinary hydroxyproline, urinary calcium excretion, bone histomorphometry
- MeSH terms
- Pamidronate, Alkaline Phosphatase, Bone Neoplasms, Bone Resorption, Calcium, Creatinine, Diphosphonates, Humans, Hydroxyproline, Male, Prostatic Neoplasms, Osteocalcin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
